01/05/2026

A substantial share of patients who undergo invasive coronary angiography for stable angina are found to have no obstructive coronary disease. And for many, that's where the workup ends. Yet, a meaningful proportion of these patients have angina with non-obstructive coronary arteries (ANOCA), ischemia with non-obstructive coronary arteries (INOCA), or coronary microvascular dysfunction (CMD): conditions that drive ongoing symptoms, repeat presentations, and are invisible on coronary angiographies. Closing this gap requires a complete coronary physiology assessment – pressure and flow, epicardial and microvascular – performed routinely and reproducibly in the cath lab. 

This is the clinical gap the iKOr System is designed to address. iKOr is an optical microcatheter and console that delivers Fractional Flow Reserve (FFR), Coronary Flow Reserve (CFR), and the Index of Microcirculatory Resistance (IMR) from a single device, over a standard 0.014″ coronary guidewire – without the saline-bolus thermodilution steps that have historically limited reproducibility of microvascular assessment. The goal is to make a comprehensive coronary physiology assessment clinically practical, and consistent, within the existing cath lab workflow. 

Following our recent Series A2 close, led by Parkwalk Advisors, we are advancing toward our FDA submission and the launch of our US clinical program. The iKOr Diagnostic Evaluation (iKoDE) study is designed to generate real-world clinical evidence and supporting publications around iKOr's role in the assessment of ANOCA, INOCA, and CMD, and to support broader US clinical adoption. 

Echopoint Medical is also a member of the HeartX Accelerator, through which we are connecting with leading US cardiovascular institutions and the MedAxiom network as we prepare for US clinical and commercial entry. 

Connecting with prospective investigator sites 

Ahead of the iKoDE study, we are now in the early stages of conversations with US cath labs interested in participating. We are particularly keen to connect with interventional cardiologists and cath lab leaders who are interested in building a structured ANOCA / CMD diagnostic program, and who see value in being part of the early US clinical experience with the iKOr System. 

If you would like to learn more, register an expression of interest, or simply start a conversation, please reach out to our VP of clinical operations, Kurt Garner –